Subacute cutaneous lupus erythematosus
MONDO:0015573Subacute cutaneous lupus erythematosus (SCLE) is a form of cutaneous lupus erythematosus (CLE) that can present either as a non-scarring, annular photo-distributed dermatosis or psoriasiform plaques. SCLE is associated with anti-Ro/SSA antibodies and can be drug-induced.
44 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
New hope for lupus skin lesions: drug trial targets stubborn cases
Disease control OngoingThis study tests a drug called litifilimab for people with lupus-related skin disease that didn't get better with standard antimalarial pills. About 450 adults with active skin lesions will receive either the drug or a placebo every 4 weeks for 24 weeks, then everyone gets the dr…
Phase: PHASE2, PHASE3 • Sponsor: Biogen • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New hope for lupus skin sufferers: Long-Term drug trial launches
Disease control ENROLLING_BY_INVITATIONThis study tests the long-term safety of the drug litifilimab in adults with lupus skin disease (CLE) that didn't improve with standard antimalarial treatment. About 322 participants who completed a prior study will receive injections every 4 weeks for up to 2 years (or 5 years i…
Phase: PHASE3 • Sponsor: Biogen • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New lupus drug enpatoran tested for long-term safety
Disease control OngoingThis study looks at the long-term safety and effectiveness of enpatoran, an experimental drug for lupus. About 379 people who completed a previous 24-week study will take different doses of enpatoran or a placebo for up to 194 weeks. The goal is to see if the drug is safe and hel…
Phase: PHASE2 • Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New shot could tame lupus skin flares
Disease control OngoingThis study tests an experimental drug called IMVT-1402 in people with lupus-related skin rashes (subacute or chronic cutaneous lupus) that haven't gotten better with standard treatments. About 56 participants will receive either the drug or a placebo for 12 weeks, then all get th…
Phase: PHASE2 • Sponsor: Immunovant Sciences GmbH • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Could a week of antibiotics stop joint infections after replacement surgery?
Disease control ENROLLING_BY_INVITATIONThis study tests whether taking a 7-day course of oral antibiotics after hip or knee replacement surgery can prevent joint infections in patients at higher risk due to conditions like obesity, diabetes, or autoimmune disease. About 4,600 participants will receive one of three ant…
Phase: PHASE4 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Experimental CAR-T therapy targets tough autoimmune conditions
Disease control TerminatedThis early-phase study tests a new type of CAR-T cell therapy in 9 people with autoimmune diseases that have not responded well to standard treatments. The therapy uses specially engineered immune cells to target and attack faulty immune cells. The main goal is to check safety an…
Phase: EARLY_PHASE1 • Sponsor: Beijing Boren Hospital • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Fetal stem cells aim to tame immune chaos
Disease control ENROLLING_BY_INVITATIONThis early-stage trial tests clonal fetal mesenchymal stem cells (cfMSCs) in 100 people with severe immune-related disorders or tissue damage. The goal is to see if the cells are safe and can reduce symptoms. Participants have no other treatment options left.
Phase: PHASE1 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug could tame lupus skin flares
Disease control OngoingThis phase 2 trial tests deucravacitinib, an anti-inflammatory pill, against a placebo in 74 adults with active discoid or subacute cutaneous lupus — skin rashes caused by lupus. The main goal is to see if the drug reduces rash severity after 16 weeks. Participants must already b…
Phase: PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 26, 2026 15:30 UTC
-
New tool could predict who will suffer from steroid side effects
Knowledge-focused OngoingThis study aims to create a tool that predicts which patients with inflammatory rheumatic diseases (like rheumatoid arthritis, vasculitis, or polymyalgia rheumatica) will develop serious side effects from long-term steroid use. Researchers will collect routine medical data—such a…
Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
New registry aims to unlock safer pregnancies for women with autoimmune conditions
Knowledge-focused ENROLLING_BY_INVITATIONThis registry enrolls up to 1,000 women aged 12–55 with rheumatic or autoimmune diseases who are pregnant or planning pregnancy. Researchers will collect data from medical records and patient surveys to study pregnancy outcomes, disease activity, and medication use. No experiment…
Sponsor: Duke University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
Immune cell showdown: autoimmune vs. infection vs. healthy
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at immune cells from people with autoimmune diseases (like lupus), people with infections, and healthy volunteers. Researchers want to understand how these cells differ and what makes them attack the body in autoimmune conditions. The study involves blood and bon…
Sponsor: Emory University • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:53 UTC